Illumina, Inc. (ILMN) Stock: Price, Forecast & Analyst Target
Illumina, Inc. (ILMN) — MoonshotScore 84/100 (Exceptional band), calculated Nov 18, 2026. Price $210.01 (+3.65%), as of the Nov 18, 2026 trading session; market cap $31.8B.
Educational signal · not a buy or sell recommendation · How to read this
Illumina, Inc. · ILMN · NASDAQ · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered): Illumina supplies sequencing and array instruments, consumables, services and support to research and clinical laboratories; it is an enabling platform for genomic analysis, not primarily a developer of individual diagnostic tests. The case now depends on whether recovering profitability and cash generation can endure while research consumables remain under pressure and newer multiomics offerings begin contributing revenue.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Illumina (ILMN)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- quarterly revenue $1.13B (Q3 FY2026, quarter ended Sep 2026)
- EPS beat 7 of the last 8 reports
- Altman Z 6.58 · Piotroski F 7
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 89 | Exceptional | |
| 88 | Exceptional | |
| 89 | Exceptional | |
| 89 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $210.01 | |
| Change on the day | +3.65% | |
| 52-week range | $112.65–$309.35 | |
| Market capitalisation | $31.8B | — |
| Price / earnings (trailing) | 34.40 | |
| Shares traded on the day | 1.63M | |
| Beta (volatility vs the S&P 500) | 1.45 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Illumina (ILMN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Illumina (ILMN), and what does it report?
Short answer · as of
Illumina sells the equipment and recurring inputs used to read and analyze genetic material.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Its customers include research institutes, universities, medical centers, public laboratories, drug developers, molecular-diagnostic providers and consumer-genomics businesses, reached through direct sales and distributors.
Sequencing supplies the overwhelming majority of reported revenue, while microarrays form a much smaller business. Reported sales combine instruments, consumables, sequencing and genotyping services, maintenance agreements, licensing arrangements and cancer-detection testing, so revenue measures activity across an installed workflow rather than demand for a single assay.
What do the latest results show for Illumina (ILMN)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $1.13B.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
The latest period delivered higher revenue than both the immediately preceding period and the comparable earlier period. Gross profit, operating profit and net income all advanced, while operating cash flow remained positive; reported revenue and earnings also exceeded prevailing estimates.
Management is not treating that improvement as proof of a broad end-market recovery. It still expects research and applied consumables to contract, while pointing to growth outside the domestic market and initial revenue from the Billion Cell Atlas and the multiomics portfolio as offsets.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
| Sep 30, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $1.13B | $220M | $1.43 (diluted) |
| Q2 FY2026 | $1.16B | $207M | $1.35 (diluted) |
| Q1 FY2026 | $1.09B | $134M | $0.87 (diluted) |
| Q4 FY2025 | $1.16B | $334M | $2.17 (diluted) |
What are the financial strengths and risks for Illumina (ILMN)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Illumina has produced positive operating cash flow throughout the quarterly series, with capital spending absorbing only a limited portion of that inflow. Profitability has also recovered sharply from the annual losses recorded before the latest profitable year, and the current margin profile reflects a business again converting a substantial share of sales into operating income.
Cash and short-term investments provide meaningful liquidity, but they do not cover total debt, leaving the company in a net-debt position. The financial risk is therefore less about immediate operating burn than about a renewed weakening in sequencing demand: softer consumable usage could pressure high gross margins while research spending and the debt burden remain.
What should you watch next at Illumina (ILMN)?
Short answer · as of
Current published price targets run low $200.00 · high $305.00 · consensus $260.00 · median $260.00 against a quoted price of $210.01 (as of Nov 18, 2026).
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
The upcoming report should be tested against management’s own operating signals: whether revenue stays near the latest run rate, whether operating profitability holds, and whether research and applied consumables continue declining despite better sequential trends. Another revenue and earnings beat would reinforce recent execution, but the composition of sales matters more than the headline surprise.
Watch for clearer contribution from the Billion Cell Atlas and multiomics portfolio, alongside continued growth outside the domestic market. Cash conversion should also remain close to the operating improvement; a divergence between profit and operating cash flow would weaken the quality of the recovery.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Illumina compare with its peers?
Short answer
Illumina's score ranks 4th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Illumina differs from test-centered diagnostics companies because it primarily supplies the sequencing infrastructure and consumables that many laboratories use across research and clinical applications. That creates exposure to laboratory activity, instrument adoption and repeat workflow usage rather than reliance on demand for a narrow menu of proprietary tests.
Sequencing dominates the revenue mix, with microarrays playing a supporting role. The combination of instruments, recurring consumables, services and maintenance also gives Illumina a broader revenue engine than a pure equipment vendor, although pressure on consumable utilization can spread quickly through the model.
| Company | Price | Market value | Score |
|---|---|---|---|
| $698.47 Nov 18, 2026 | $55.0B | 96 5-pillar Nov 18, 2026 | |
| $1737.26 Nov 18, 2026 | $34.6B | 93 5-pillar Nov 18, 2026 | |
| $646.87 Nov 18, 2026 | $18.1B | 92 5-pillar Nov 18, 2026 | |
| Illumina (ILMN) — this page | $210.01 | $31.8B | 84 |
| $177.33 Nov 18, 2026 | $50.0B | 83 5-pillar Nov 18, 2026 | |
| $259.52 Nov 18, 2026 | $28.6B | 74 5-pillar Nov 18, 2026 | |
| $195.16 Nov 18, 2026 | $14.6B | 73 5-pillar Nov 18, 2026 | |
| $50.97 Nov 18, 2026 | $31.4B | 72 5-pillar Nov 18, 2026 | |
| $370.78 Nov 18, 2026 | $30.1B | 71 5-pillar Nov 18, 2026 | |
| $257.84 Nov 18, 2026 | $42.5B | 71 5-pillar Nov 18, 2026 | |
| $152.43 Nov 18, 2026 | $17.0B | 71 5-pillar Nov 18, 2026 | |
| $333.25 Nov 18, 2026 | $16.0B | 70 5-pillar Nov 18, 2026 | |
| $466.10 Nov 18, 2026 | $91.6B | 60 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $200.00 – $305.00
- Consensus target
- $260.00
- Median target
- $260.00
Consensus record · Captured .
Measured against a quoted price of $210.01 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 11, 2026
- Transactions
- 100
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 89
- Other transactions
- 11
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ILMN in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| ARK Invest | Cathie Wood | Q3 2026 | 1.34% | $233.12M | Trimmed −18.5% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Illumina (ILMN)?
Common Questions About ILMN (Healthcare)
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why do Illumina research consumables matter so much?
Consumables capture recurring sequencing activity after laboratories adopt Illumina workflows, making their usage an important indicator of customer throughput. Management still expects contraction in research and applied consumables, so sequential improvement alone does not establish a durable recovery.
What could the Billion Cell Atlas change for Illumina?
The Billion Cell Atlas is beginning to contribute revenue and gives Illumina another route into expanding genomic workflows. Its significance will depend on whether that contribution becomes material alongside broader customer interest in multiomics.
Is Illumina mainly a sequencing company or a microarray company?
Sequencing accounts for the dominant share of segment revenue, while microarrays are considerably smaller. Illumina’s economic exposure therefore rests chiefly on sequencing instruments, consumables and related services.
Can Illumina fund its debt from current liquidity?
Cash and short-term investments fall short of total debt, so current liquidity does not eliminate leverage. Positive operating cash flow and modest capital spending provide an internal funding cushion, but continued cash conversion remains important.
What is the ILMN stock price today?
The last price recorded for Illumina, Inc. (ILMN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ILMN price target?
The analyst consensus price target for Illumina, Inc. (ILMN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 26 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold ILMN
Funds in our ETF coverage that list ILMN among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Global X - Genomics & Biotechnology ETF (GNOM) | 5.13% | |
| Invesco S&P MidCap Quality ETF (XMHQ) | 3.73% | |
| IVOO ETF | 0.66% |